Cancer Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer

Table of Contents

RECENT HIGHLIGHTS AND CHANGES
--Recent Highlights and Changes
UPCOMING PATENT EXPIRES BY THERAPY AREA
Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Pipeline Overview
--% of Projects (By Phase of Development)
--No. of Projects by Phase of Development
--Marketed Products Vs. Pipeline Products
Company Overview - Pipeline Projects
--Company Overview - Pipeline Projects

--Top Companies in late stage Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Projects
--Amgen Inc
--Abbott Laboratories
--Boehringer Ingelheim GmbH
--AstraZeneca Plc
--Celgene Corporation
--Bristol-Myers Squibb Company
--Eli Lilly & Co
--Eisai Co Ltd
--GlaxoSmithKline plc
--Genentech Inc
--Merck KGaA
--Imclone Systems Inc
--OXiGENE INC
--OSI Pharmaceuticals Inc
--Pharmacyclics Inc
--Pfizer Inc
--Roche Holdings Ltd
--PharmaMar
--Telik Inc
--Spectrum Pharmaceuticals Inc

--Top Companies in early stage Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Projects
--Alfacell Corp
--Active Biotech
--AmpliMed Corporation
--Allos Therapeutics Inc
--Antisense Pharma GmbH
--Anavex Life Sciences Corp.
--Archemix Corp.
--Antisoma PLC
--Bristol-Myers Squibb Company
--Ariad Pharmaceuticals Inc
--LEO Pharma A/S
--Introgen Therapeutics Inc
--Medisyn Technologies, Inc.
--MEABCO A/S
--Peregrine Pharmaceuticals Inc
--Patrys Limited
--Silence Therapeutics plc
--erly SR Pharma plc)
--Raven biotechnologies, inc.
--Topotarget A/S
--Takeda Pharmaceutical Company Limited

Pipeline Revenue
--Pipeline Revenue
Full Pipeline View
--Pre Clinical Pipeline View
--Phase I Pipeline View
--Phase II Pipeline View
--Phase III Pipeline View
--Pending Approval Pipeline View
--Approved Pipeline View
--On the Market Pipeline View
--Discovery/Development Pipeline View